Company Interview / Momentum builds as Alcidion upgrades earnings

Kate Quirke CEO of Alcidion (ASX:ALC) shares insights into their upgraded earnings guidance for FY25, anticipating to exceed $3 million. Alcidion sees strong cash flow and revenue from TCV sales, especially in the UK, where it constitutes around 50% of their revenue.

Kate highlights a milestone contract in North Cumbria and their first contract in Wales, indicating robust growth in the UK. She sees digital technology and AI as key to improving productivity and efficiency in healthcare, enhancing patient experiences while optimizing clinical resources.

Expansion opportunities are being eyed in Canada and the Middle East due to their similar healthcare systems and digital investment. Kate notes a shift from US to alternative digital suppliers as a potential growth avenue. Alcidion (ASX:ALC) remains open-minded about strategic acquisitions.